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Abstract
It was previously reported that injection of anaflatoxin B1 (AnAFB1) conjugated to keyhole limpet hemocyanin (KLH),
together with Freund’s adjuvant, was effective in inducing in cows a long lasting titer of anti-aflatoxin B1 (AFB1) antibodies
(Abs), cross-reacting with other aflatoxins, which were able to hinder, proportionally to their titer, the secretion of aflatoxin
M1 (AFM1) into the milk of cows continuously fed with AFB1. According to anti-AFB1 Ab titer, 50% of the vaccinated cows
were recognized as high responder animals. In an attempt to prepare a more effective formulation for vaccination of cows,
it was compared the immunogenicity, in Holstein Friesian heifers, of AnAFB1 covalently conjugated to KLH or to
recombinant diphtheria toxin (CRM197) molecules, and injected together with various adjuvants. This study demonstrated
that injection of AnAFB1 conjugated to KLH and mixed with complete (priming) and incomplete Freund’s adjuvant
(boosters), as in the previous schedule of immunization, was the most effective regimen for inducing Ab responses against
AFB1, although pre-calving administration could increase the effectiveness of vaccination, resulting in 100% high responder
animals. After one booster dose at the beginning of the milk production cycle, anti-AFB1 Ab titers were comparable to those
recorded at the end of the immunization schedule, and proved to be effective in reducing significantly AFB1 carry over, as
AFM1, from feed to milk. Pre-calving vaccination of dairy heifers with conjugated AnAFB1, adjuvated with complete and
incomplete Freund’s adjuvant, may represent the most effective tool for preventing the public health hazard constituted by
milk and cheese contaminated with aflatoxins.
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Introduction
Aflatoxins (AFs) are a group of mycotoxins produced mainly by
strains of Aspergillus flavus and A. parasiticus. Over 20 AFs and
derivatives have been isolated, but the major natural occurring
AFs of fungal origin are B1, B2, G1, and G2, the B1 (AFB1) being
the most important compound with respect to both prevalence
and toxicity for man and animals [1].
Even if cases of acute intoxication may also occur, chronic
toxicity of AFs is the most serious concern due to the estimated size
of population at risk and the detrimental health effects associated
with chronic aflatoxicosis [2,3]. Chronic consumption of AFs has
been identified as one of the major risk factors for the development
of hepatocellular carcinoma and AFs are classified as Group 1
carcinogens by International Agency for Research on Cancer [2].
Furthermore, evidence suggests a relation between chronic AFs
exposure and malnutrition, impaired growth, immunosuppression,
and, consequently, susceptibility to infectious diseases [3].
In the liver, part of ingested AFB1 is biotransformed into the
hydroxy derivative M1 (AFM1), which is then excreted into the
milk of lactating mammals, including dairy animals [4]. As a
result, AFB1 can pass through the food chain from animal feeds
into milk as AFM1 (carry over). The occurrence of AFM1 in milk
and its derivatives is a serious problem of food safety, and many
countries defined specific limits for AFM1 in the milk and for AFB1
in the feed of dairy animals [5]. In spite of the strict selection of
raw materials used for the manufacturing of feeds, production of
AFM1-free milk is not always achieved and many surveys reported
high levels of contamination of milk and milk derived food for
humans and infants [6–9]. Furthermore, concern has been raised
for the possible adverse cumulative effects of low amounts of
AFM1, which could be present beneath the legal limit [10].
Physical, chemical and biological methods which have been tried
for complete detoxification of AFM1 don’t fulfill the efficacy,
safety, and cost requisites of the task [11]. Addition to feeds of
sequestering agents, able to bind selectively AFs, does not
guarantee a complete prevention of AFs absorption in the
gastro-intestinal tract, and some of them have been suspected to
interfere with the assumption of micronutrients [12–14].
It was previously described an alternative prophylactic ap-
proach relying on an experimental vaccine based on the
immunogen anaflatoxin B1 (AnAFB1), a non-toxic and non-
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mutagenic chemically modified preparation of AFB1, coupled to
keyhole limpet hemocyanin (KLH) as carrier [15]. AnAFB1-KLH,
administered with complete (priming) and incomplete Freund’s
adjuvant (boosters), was effective in inducing in cows a long lasting
titer of anti-AFB1 antibodies (Abs) which were able to hinder the
carry over of AFB1 as AFM1 into the milk of cows continuously fed
with AFB1, without interfering with intradermal tuberculin test
results. In particular, 50% of the vaccinated cows were recognized
as low responder and 50% as high responder animals. For the
latter, up to 46% reduction of average AFM1 in milk was
recorded, as compared to animals immunized with KLH [15].
Whether AnAFB1-KLH conjugates would lose immunogenicity or
be equally or more immunogenic when combined with other
adjuvants was untested. Effect of conjugation of AnAFB1 with
other protein carriers and effect of variations in the vaccination
schedule on the immune response to AnAFB1 were unknown as
well.
The aim of this work was to comparatively study the AFB1-
specific Ab response in Holstein Freisian heifers immunized
systemically with AnAFB1 conjugated with KLH and CRM197
carrier proteins and administered with Freund’s adjuvant or
aluminium hydroxide gel as immunological adjuvants, in order to
select the most effective anti-AFB1 vaccine to further reduce AFM1
transfer in milk of cows exposed to AFB1.
Materials and Methods
Ethics statement
The research protocol and animal care were in accordance with
the EC Council Directive guidelines for animals used for
experimental and other scientific purposes [16].
The study has been approved by the local health authority
‘‘Azienda Unita` Sanitaria Locale di Piacenza’’ (protocol number
50226) and by the National Ministry of Health according to
legislative decree 116/92.
Preparation of protein conjugates of AnAFB1
The immunogen AnAFB1, prepared converting AFB1 (Sigma-
Aldrich, St. Louis, MO, USA) to AFB1-1(O-carboxymethyl) oxime
using the method of Chu et al. [17], as previously described [15],
was conjugated to KLH (Sigma-Aldrich) or CRM197 (List
Biological Laboratories Inc., Campbell, CA, USA) to be used as
immunogen. The coupling reaction to KLH was carried out using
a method previously described [18]. N-hydroxysuccinimide
(0.047 mmol) and N,N’-diisopropylcarbodiimide (9.3 mmol), dis-
solved in 600 ml of dimethylformamide (DMF), were added to
AnAFB1 (5.19 mmol) in 600 ml of dry dichloromethane at 0uC,
followed by 4-(dimethylamino)pyridine (0.041 mmol). Then, the
active ester was slowly added to a pre-cooled aqueous buffered
solution (31 mM Na2HPO4, pH 9.1) containing 20 mg KLH and
not more than 10% (v/v) DMF. The mixture was kept at 4uC
overnight, and then the conjugate was separated from unreacted
reagents and by-products, desalted and extensively dialyzed
against PBS by using a 10 kDa cut-off centrifugal filter tube
(Microcon YM-10, Millipore Corporation, Bedford, MA, USA).
The water soluble carbodiimide method was used to conjugate
AnAFB1 to CRM197 [19–22]. Briefly, AnAFB1 (1.6 mmol),
dissolved in 31 ml of dimethyl sulfoxide, and CRM197 (0.16 mmol)
were mixed in 1 ml of conjugation buffer (0.1 M 2-[N-morpho-
lino] ethane sulfonic acid, 0.5 M NaCl, pH 5.0). Immediately
prior to use, 10 mg of 1-ethyl-3-(3-dimethyl aminopropyl)
carbodiimide hydrochloride (EDC) and 25 mg N-hydroxysulfo-
succinimide (sulfo-NHS) were dissolved in 1 ml cold deionized
water, and 500 ml EDC/sulfo-NHS solution were added to the
reaction mixture. The reaction was continued for 2 h at room
temperature with slow tilt rotation, after which hydroxylamine
(final concentration 10 mM) was added to quench the reaction.
The solution was incubated for 15 minutes at room temperature
with slow tilt rotation. The conjugate was separated from
unreacted reagents and by-products, desalted, and extensively
dialyzed against PBS by centrifugation as described above.
The protein concentration was determined by using the
Bradford method, using BSA (electrophoresis fractionated;
Sigma-Aldrich) as external standard [23]. The amount of
conjugated AnAFB1 was estimated based on the molar absorptiv-
ity of 20,950 (lNmol21Ncm21) at 362 nm [24]. The ratio between
the concentration of the bound toxin and that of the protein gave
the loading degree of the conjugate. Two batches of the AnAFB1-
KLH conjugate were produced at different times and were
labelled as batch I and II. A loading degree of 6.4 and 8 mol
AnAFB1:1 mol KLH was determined for batch I and II,
respectively. A loading degree of 1 mol AnAFB1:1 mol CRM197
was determined. The conjugates were lyophilized and stored at
220uC before being used for immunization.
Immunization of heifers with different vaccine
formulations
Nineteen italian Holstein Friesian heifers (age of 1861.5
months) housed at the CERZOO research and experimental
center (San Bonico, Italy) were used for experimental immuniza-
tion. The animals had free access to water and were fed ad libitum.
The diet was composed by corn silage (408 g/kg), grass hay
(408 g/kg), straw (102 g/kg), soybean meal (75 g/kg) and mineral-
vitamin commercial mix (7 g/kg). On a dry matter basis (DM,
525 g/kg), the diet chemical composition was as follow: starch
264 g/kg DM, neutral detergent fiber 345 g/kg DM, and crude
protein 165 g/kg DM.
The animals were regularly inspected by the veterinary services
of the local health authority (Azienda Unita` Sanitaria Locale). An
official intradermal tuberculin test was carried out before starting
and after the end of the vaccination schedule, and interpreted
according to EC Commission Regulations [25]. The heifers were
divided into groups of three or four and immunized at three weeks
intervals with four doses (1 ml each) of one of six vaccine
preparations: 1) 500 mg of batch I AnAFB1-KLH in complete (first
dose) and incomplete (subsequent doses) Freund’s adjuvant
(Sigma-Aldrich) in a 1:1 (vol/vol) ratio; 2) 500 mg of batch II
AnAFB1-KLH in complete (first dose) and incomplete (subsequent
doses) Freund’s adjuvant in a 1:1 (vol/vol) ratio; 3) 500 mg of batch
II AnAFB1-KLH in incomplete Freund’s adjuvant in a 1:1 (vol/
vol) ratio; 4) 500 mg of batch II AnAFB1-KLH in aluminium
hydroxide gel (Sigma-Aldrich) in a 1:1 (vol/vol) ratio; 5) 300 mg of
AnAFB1-CRM197 in complete (first dose) and incomplete (subse-
quent doses) Freund’s adjuvant in a 1:1 (vol/vol) ratio; 6) 300 mg of
AnAFB1-CRM197 in aluminium hydroxide gel in a 1:9 (vol/vol)
ratio. Animals of groups 1 and 2 received a fifth vaccine dose four
months after calving, i.e. at the age of 3161 months. Each vaccine
preparation in Freund’s adjuvant was administered intramuscu-
larly in the neck, and each vaccine preparation in aluminium
hydroxide gel was administered subcutaneously in front of the
shoulder. The immunization schedule is summarized in Table 1.
Animals of group 1 could be considered as a positive control of
immunization as they received the same formulation previously
described in lactating dairy cows [15].
Animals were bled via the jugular artery prior to each
immunization and two weeks after last booster. Animals of groups
1 and 2 were bled at scheduled times thereafter. Blood was stored
60 min at 37uC to allow clotting, centrifuged (1500 g, 10 min,
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room temperature), and the serum fraction aspirated and stored at
220uC.
Enzyme-linked immunosorbent assay (ELISA)
Detection and titration of specific anti-AFB1 Abs were carried
out by ELISA, as previously described [15]. Briefly, serially ten-
fold diluted (from 1:4 and 1:10 to 1:400,000) immune serum or
control (pre-immune serum) was added to each well of polystyrene
microtiter plates coated with AFB1-BSA conjugate (Sigma-Aldrich)
or BSA control protein. After incubation, reaction was detected by
adding rabbit anti-bovine IgG (whole molecule) peroxidase
conjugate Abs (Sigma-Aldrich, product number A7414) and
chromogen/substrate solution. The optical density (OD) at
450 nm was read by using a Multiskan Ascent spectrophotometer
(Labsystems, Helsinki, Finland), and the titer of each immune
serum was defined as the inverse of the highest dilution that gave
0.1 OD above the pre-immune serum at the same dilution. To
compensate for between-plate variability, individual plates were
normalized to the mean of the appropriate positive control. For
statistic evaluation the logarithms of anti-AFB1 Ab titers were
considered.
Treatment of dairy cows with AFB1
Two months after last vaccine dose, an AFB1 contaminated diet
was administered to animals of group 1 (n= 3), group 2 (n = 3),
and unvaccinated animals (control group, n= 6). On average,
animals had an age of 3361 months, 219.4621 days in milk, and
average milk yield of 28.766.3 kg/day/cow. Basal diet samples
were collected on days 0 and 11 of the experimental period, dried
at 55uC in a ventilated oven to constant weight, and then ground
with a 1 mm sieve (Thomas-Wiley Laboratory Mill, Arthur H.
Thomas Co., Philadelphia, PA, USA) and frozen until analysed for
AFs. The AFB1 content in the basal diet, measured by HPLC-
fluorescence after immunoaffinity separation, as previously
described [15], was 0.1360.01 mg/kg, corresponding to about
2.860.25 mg/cow/day based on an estimated ingestion of
21.5 kg/cow/day dry matter. On the days of experiment, animal
were given via oral drench, before feeding, a bolus of naturally
AFB1-contaminated corn meal in about 300 g of AFB1-free soy
bean meal, giving a calculated daily AFB1 total ingestion of
10260.1 mg. AFB1 contents of different supplied batches were
tested and results demonstrated a good homogeneity. Considering
the estimated average ingestion, a corresponding AFB1 contam-
ination of 4.74 mg/kg of diet could be calculated, a value in the
range commonly reported on standard field conditions [26,27].
Experimental periods lasted 16 days, consisting of 11 days of
intoxication and 5 days of clearance (no AFB1 in the diet).
Individual milk samples were collected at day 0, 1, 3, 5, 7, 9, 11,
12, 14, and 16. A representative sample for each day of milking
was obtained and stored at 218uC for subsequent analysis.
Quantification of AFM1 in milk samples and carry over
calculation
AFM1 was quantified by HPLC in milk samples defatted by
centrifugation, filtered, and passed through an immunoaffinity
column, as previously described [15].
The carry over rate of AFB1 in milk as AFM1 was calculated as
the percentage ratio between the daily amount of AFM1 excreted
in milk at the plateau condition and the daily amount of AFB1
ingested by the animals.
Statistical analyses
All data were presented as means 6 standard deviations (SD),
and analysed as repeated measurements according to a completely
randomized design. In particular, the statistical model adopted for
data collected over time from different groups (anti-AFB1 Ab titers
and AFM1 concentration at steady-state condition) included the
fixed effects of treatment, time of measurement and treatment6
time of measurement interaction. The steady-state condition of
AFM1 was determined as suggested by Littell et al. [28]. To assess
persistence of specific Abs over time, anti-AFB1 titers were
analysed considering the fixed effect of time of measurement.
Cows within groups were the subject of repeated measurements.
Least square means (LSMeans) were post-hoc compared by using
Tukey multiple comparison test. P values,0.05 were considered
significant, while P between 0.05 and 0.10 were considered as a
trend.
Results
Titration of anti-AFB1 Abs
The titers of specific anti-AFB1 Abs detected by ELISA in sera
from individual heifers immunized either with AnAFB1-KLH or
AnAFB1-CRM197 are shown in Table 2. For all of the heifers, pre-
immune control sera showed negligible binding to AFB1-BSA.
When sera were incubated with control BSA (unconjugated), only
a very low degree of nonspecific binding was detected (data not
shown). Heifers of groups 1 and 2, primed with batch I and II
AnAFB1-KLH in complete Freund’s adjuvant showed a titer of
anti-AFB1 Abs of 10,000 after injection of the second dose in
Table 1. Immunization schedule.
Group Antigen Adjuvant N Route
1 AnAFB1-KLH, batch I CFA (priming), IFA (boosters) 3 i.m.
2 AnAFB1- KLH, batch II CFA (priming), IFA (boosters) 3 i.m.
3 AnAFB1-KLH, batch II IFA 3 i.m.
4 AnAFB1-KLH, batch II AlOH3 4 s.c.
5 AnAFB1-CRM197 CFA (priming), IFA(boosters) 3 i.m.
6 AnAFB1-CRM197 AlOH3 3 s.c.
CFA: complete Freund’s adjuvant; IFA: incomplete Freund’s adjuvant; AlOH3: aluminium hydroxide gel; i.m.: intramuscular; s.c.: subcutaneous; N: number of heifers per
group. Immunization consisted of a priming dose (day 0) of 500 mg AnAFB1-KLH or 300 mg AnAFB1-CRM197 with adjuvant, as indicated, followed by three doses with the
same amount of conjugate with adjuvant, as indicated, at intervals of three weeks. Animals of groups 1 and 2 received a fifth vaccine dose 4 months after calving, which
was at age of 2761.1 months. A loading degree of 6.4 and 8 mol AnAFB1:1 mol KLH was determined for batch I and II, respectively. A loading degree of 1 mol AnAFB1:1
mol CRM197 was determined.
doi:10.1371/journal.pone.0094440.t001
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incomplete Freund’s adjuvant. After the third dose only one heifer
belonging to group 1 showed an Ab titer of 40,000. The fourth
injection did not increase the Ab titer observed after the first three
doses (P.0.05). Heifers of group 3, primed and boosted with batch
II AnAFB1-KLH in incomplete Freund’s adjuvant, reached a peak
(titers of 400 or 1,000) after the second dose. The titers of two
heifers declined thereafter. At week 11, after the administration of
four doses of the vaccine, the average Ab titer of this group was
lower than the ones of groups 1 and 2 (P,0.05). Immunization
with 4 doses of batch II AnAFB1-KLH in alum induced no
detectable anti-AFB1 Ab titers in any of the heifers of group 4 (data
not shown). Priming with AnAFB1-CRM197 in complete Freund’s
adjuvant and injection of the second dose in incomplete Freund’s
adjuvant did induce anti-AFB1 Ab production in 3 out of 3 heifers
of group 5. However, the average Ab titer of this group was not as
high as those in AnAFB1-KLH immunized heifers of groups 1 and
2 (P,0.05). Administration of AnAFB1-CRM197 in alum induced
anti-AFB1 Ab production in 2 out of 3 heifers of group 6. After the
administration of four vaccine doses, average Ab titer of group 6
was comparable to that of group 3 (P.0.05) and lower than those
of group 5 (P,0.05).
In Table 3 is summarized the anti-AFB1 response among the
vaccinated heifers in terms of high-responder (anti-AFB1 Ab titer
$10,000), low-responder (titer between 1,000 and ,10,000) and
non-responder (titer,1,000) animals at the end of the vaccination
schedule.
At the end of the vaccination, cows of groups 1 and 2 presented
no difference (group effect not significant) in anti-AFB1 Ab titers
(P.0.05). Batch I and II vaccines were therefore considered as
replicates of same treatment and the high responders animals of
groups 1 and 2 were pooled for subsequent monitoring and carry
over studies.
The vaccination regimen did not induce delayed hypersensitiv-
ity to Mycobacterium tuberculosis in any of the vaccinated heifers, as
demonstrated by negative intradermal tuberculin test.
Monitoring of anti-AFB1 Abs
Anti-AFB1 Ab titers of selected high responder animals were
monitored at scheduled times to assess persistence of specific Abs
over time and to evaluate the influence of pregnancy and partum
on the immunological status of animals. As shown in Figure 1,
anti-AFB1 Ab titers declined over time following vaccination. No
difference (P.0.05) was observed between titers recorded in sera
collected 15 days before the time of expected parturition and 15
day after partum, indicating that physical and metabolic stresses
associated with late pregnancy, calving, early lactation, and peak
milk yield had no effects on the titer of anti-AFB1 Abs.
After one booster dose at the beginning of the milk production
cycle, anti-AFB1 Ab titers increased (P,0.05) with values ranging
between 10,000 and 40,000 at 14.6 months post priming, the
booster being effective to retrieve an Ab response against AFB1.
Subsequently, titers declined over time, while administration of
AFB1 in the diet had no effect on anti-AFB1 Ab decrease (P.0.05).
Table 2. Anti-AFB1 Ab titers in vaccinated heifers.
Group Cow Anti-AFB1 Ab titer
Week 0 Week 3 Week 6 Week 9 Week 11
1 415 0 3.00 4.00 4.60 4.60
418 0 3.00 4.00 4.00 4.00
422 0 2.60 4.00 4.00 4.00
Average 0±0 2.87±0.23 4.0±0 4.2±0.35 4.2±0.35
2 412 0 3.60 4.00 4.00 4.00
421 0 3.00 4.00 4.00 4.00
425 0 3.60 4.00 4.00 4.00
Average 0±0 3.4±0 4.0±0 4.0±0 4.0±0
3 432 0 2.60 2.60 2.00 0.00
433 0 2.00 3.00 3.00 3.00
434 0 2.00 2.60 2.00 2.00
Average 0±0 2.20±0.35 2.73±0.23 2.33±0.58 1.67±1.53
5 410 0 0 2.00 3.60 3.00
419 0 2.00 3.00 3.60 3.60
428 0 0 3.00 4.00 4.00
Average 0±0 0.67±1.15 2.67±0.58 3.73±0.23 3.53±0.50
6 411 0 0 0 0 0
423 0 0 2.60 3.00 3.00
426 0 2.60 3.00 3.00 3.00
Average 0±0 0.87±1.50 1.87±1.63 2.00±1.73 2.00±1.73
Heifers of different groups were immunized according to the schedule reported
in Table 1. For all the groups, booster injections were performed at week 3, 6,
and 9. Ab titers were determined by the method described in the text. The titer
of each immune serum was defined as the inverse of the highest dilution that
gave 0.1 OD above the pre-immune serum at the same dilution and presented
in table on a logarithmic scale for comparative purposes (undetectable anti-
AFB1 Abs were assigned a value of 0). The fixed effects of ANOVA (i.e., week,
group and their first order interaction) were significant at P,0.05 and
comparisons of interest among means were described in the text.
doi:10.1371/journal.pone.0094440.t002
Table 3. Distribution of high, low and non-responders among vaccinated heifers.
Anti-AFB1 Ab titer
Non-responder (titer ,1,000) Low-responder (titer 1,000-,10,000) High-responder (titer $10,000)
Group 1 (n = 3) - - 3
Group 2 (n = 3) - - 3
Group 3 (n = 3) 2 1 -
Group 4 (n = 4) 4 - -
Group 5 (n = 3) - 2 1
Group 6 (n = 3) 1 2 -
doi:10.1371/journal.pone.0094440.t003
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Quantification of AFM1 in milk samples and carry over
calculation
The efficacy of anti-AFB1 Abs in reducing the carry over of
AFB1 as AFM1 into milk was evaluated following parturition and
starting of milk production by monitoring AFM1 concentrations in
milk. Basal diet AFB1 level contributed to a milk AFM1
contamination of 2.6361.11 ng/kg, as measured in milk sampled
on day 0. Results of AFM1 quantification in the milk collected
from cows vaccinated when heifers and control unvaccinated cows
during the intoxication period (102 mg of AFB1 per cow per day) are
shown in Figure 2. AFM1 concentration in milk increased at every
milking and reached a steady-state condition from day 5 of
intoxication period for both groups, showing a similar behavior
among animals, the random cow effect not being significant. On
day 11, when AFB1 administration was stopped, the mean AFM1
concentration decreased quickly to return at the base line on day
16. AFM1 concentrations recorded in the milk of control cows
were consistent with carry over rates observed under field
conditions [29].
Figure 1. Monitoring of anti-AFB1 Ab titers. Mean anti-AFB1 Ab titers of high responder cows (n = 6) following vaccination with AnAFB1-KLH in
complete (first dose) and incomplete (3 boosters at three weeks intervals) Freund’s adjuvant. Two animals were removed from treated group (at 13.8
and 20.8 months post priming, respectively) for health injuries unrelated to vaccination. Partum was at an average of 9.660.75 months after first dose
vaccine administration. Data are presented (on a logarithmic scale) as mean and SD.m, fourth dose of vaccine (2.1 months); , booster (13.8 months);
, partum (9.660.75 months); n, AFB1 administration (15.6 months). Titers corresponding to points with different subscripts (a, b, c, d) differ
significantly as post-hoc evaluation by Tukey’s test (P,0.05).
doi:10.1371/journal.pone.0094440.g001
Figure 2. Average AFM1 concentration in milk. Six vaccinated (X) and six unvaccinated control (m) cows were fed 102 mg of AFB1/day from day
1 to day 11. Data are presented as mean 6 SD. Within each day, differences between vaccinated and control cows are marked (**P,0.10, *P,0.05).
doi:10.1371/journal.pone.0094440.g002
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At the steady state condition, the average AFM1 concentration
in milk collected from vaccinated cows was 74% lower than in
milk of control animals (P,0.05). Similarly, the carry over rate
calculated in vaccinated cows (0.77%) was lower with respect to
control animals (3.40%) (P,0.05) (Table 4).
Discussion
In a previous work it was reported an alternative approach for
the prevention of AFB1 carry over as AFM1 in cow’s milk, relying
on an experimental KLH-conjugate vaccine based on the antigen
AnAFB1 [15]. The vaccine was effective in inducing in cows long
lasting anti-AFB1 Abs, and Ab responses were highly predictive of
reduction of AFB1 carry over as AFM1 into the milk following
ingestion of contaminated feed. On the basis of the anti-AFB1 Ab
titer, cows were categorized into high responders (titers of 10,000
or higher) and low responders (titers between 1,000 and ,10,000).
As compared to unvaccinated controls, in high responders cows a
reduction up to 46% of average AFM1 in milk was recorded [15].
The purpose of this work was to present further developments of
this anti-AFB1 experimental vaccine, in order to obtain a more
potent Ab response and then to increase prevention of AFB1 carry
over as AFM1 from feed to milk in vaccinated cows.
Several factors, including the selection of the carrier protein and
adjuvant are known to affect the immunogenicity of conjugate
vaccines [30,31]. To study the effect of the carrier protein on
AnAFB1 immunogenicity, the antigen was covalently coupled to
CRM197, a non-toxic mutant of diphtheria toxin [32] which
demonstrated, in several vaccines, both safety and consistent Ab
induction against the immunizing antigens [33]. AnAFB1-KLH
and AnAFB1-CRM197 conjugates were formulated with incom-
plete Freund’s adjuvant and aluminium hydroxide, two adjuvants
approved for the development of commercial vaccines in
veterinary medicine, as well as with complete Freund’s adjuvant
used for previous studies. The immunogenicity and protective
performances against AFB1 carry over from feed to milk were
compared after administration of the different vaccine formula-
tions.
To study the effect of animal age on anti-AFB1 response, and
assess the possibility to confer protection from the beginning of the
milk production cycle, the vaccines were administered to young
heifers before calving. In particular, 3 or 4 heifers were immunized
for each vaccine preparation (Table 1). The number of animals
could be considered quite small and this could represent a possible
limit of current results. Anyway, the low intra-group Ab titers
variability (Table 2) seemed to have not reduced the power of
adopted tests to verify differences.
Immunogenicity of the AnAFB1 antigen either conjugated to
KLH or CRM197 was affected by administration together with
different adjuvants. In fact, while KLH was a more potent carrier
than CRM197 in Freund’s adjuvant, CRM197 was a more potent
carrier than KLH in aluminium hydroxide. AnAFB1-KLH with
complete (priming) and incomplete Freund’s adjuvant (boosters)
was the most effective formulation for inducing Ab responses
against AFB1, and consistently high titers of Ab specific to AFB1
were induced in all of the heifers. Although Freund’s complete
adjuvant is known to produce a strong and long-lasting immunity
to a broad range of antigens, concerns over severe injection-site
reactions and its potential carcinogenicity hinder its use as an
adjuvant for human vaccines, and Freund’s complete adjuvant is
not recommended for animal use in certain countries [34]. The
use of Freund’s complete adjuvant in the first dose of the vaccine
proved to be necessary to obtain a potent anti-AFB1 response. On
the other hand, after a single administration of AnAFB1-KLH in
complete Freund’s adjuvant and boosters in incomplete Freund’s
adjuvant no adverse effects on animal health and milk production
traits were observed. Moreover, any interference with the primary
diagnostic test for bovine tuberculosis was excluded.
The data obtained suggest that pre-calving administration can
increase the effectiveness of vaccination, resulting in 100% high
responder animals, while the same formulation administered in
lactating dairy cows was previously shown to result in 50% high
responder animals [15]. Moreover, anti-AFB1 Abs reached a peak
after the third dose of vaccine.
Anti-AFB1 Ab titers of vaccinated heifers decreased during
pregnancy and after calving but, after one booster dose at the
beginning of the milk production cycle, titers returned to levels
comparable to the ones obtained at the end of the immunization
schedule. This finding suggests that an annual booster could be
proposed to maintain a suitable protection. Anti-AFB1 Abs proved
to be effective in reducing significantly AFB1 carry over as AFM1
in milk following ingestion of contaminated feed. While transfer of
AFM1 in milk of control animals was consistent with carry over
rates observed under field conditions, carry over of AFB1 as AFM1
was reduced to 0.77% in vaccinated heifers, resulting in a 74%
reduction of AFM1 concentrations in milk.
Overall, the results of this study indicate that vaccination of
heifers prior to calving could confer protection from AFB1 carry
over as AFM1 in milk from the beginning of the milk production
cycle. Easy detection of anti-AFB1 Abs could allow monitoring the
immunological status of milk animals in order to determine the
protective titer and evaluate the need for booster injections.
Reduction of AFM1 in milk obtained in vaccinated cows was
notably higher than the one that can be obtained by inclusion in
animal diet of sequestering agents, able to prevent AFs absorption
in the gastro-intestinal tract [35,36]. Addition of sequestering
agents could reduce AFM1 transfer in the milk of no more than
50%, depending on the extent of contamination, animal species,
site of AF absorption, method of addition to diets, and dose
[26,37–39].
Vaccination is economically sustainable, the resulting protection
could persist over a whole milk production cycle, and alternative
treatments, such as AFs sequestering agents, could be associated,
in presence of high contamination of feed [15].
Vaccination can contribute significantly to the primary objec-
tive of minimizing population exposure to AFM1. Abs induced in
cows after vaccination may in fact capture even small amounts of
AFB1, preventing the presence of AFM1 in concentrations which,
although lower than the legal limits, may determine problems
Table 4. Average concentration of AFM1, total excretion of
AFM1, carry over rate, and milk production traits.
Controls Vaccinated
AFM1 (ng/kg) 118617 31628
Total AFM1 (mg/cow/day) 3.4760.70 0.7960.58
Carry over (%) 3.4063.82 0.7760.57
Milk production (kg/day) 32.1362.82 32.2562.96
Milk fat (g/kg) 36.260.30 36.560.42
Milk crude protein (g/kg) 34.260.28 33.860.26
The values were calculated at the steady state condition (days 5, 7, 9 and 11) in
groups of cows with average daily production of 28.766.3 kg of milk, subjected
to ingestion of 102 mg AFB1/cow/day.
doi:10.1371/journal.pone.0094440.t004
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related to chronic intake over time. Vaccination of dairy cattle
could also ensure better health quality of milk and milk products
when contamination cannot be maintained within acceptable
limits by currently used methods.
Although some other factors, such as the fate of AFB1 captured
by Abs or the consequences of accidental ingestion of very high
amount of AFB1, should be further investigated, vaccination of
dairy animals against AFB1 constitutes a feasible alternative
measure which could significantly reduce the threat to human
health posed by AFs.
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